| Activism insight

Why did the founder and former Chairman and CEO lose his election at MiMedex?

by | Nov 5, 2019

Generally, when a founder or former executives launch a proxy campaign, investors view it with great interest. The general argument is this; the founders love the company, they know the company very well, and can fix the problems.

This was not the case with MiMedex.

In April 2019, Parker H. Petit, former chairman of the board and CEO from 2009 to 2018, nominated David J. Furstenberg, Shawn P. George and himself for election to the board. However, he garnered only 16% of the votes (including his ownership of 4.3%).

When Petit launched the campaign, the company argued that Petit had engaged in material misconduct and engaged in improper accounting practices. Moreover, all three proxy advisory firms recommended shareholders to vote against Petit.

Key takeaway
Not all investors who agitate for change have “shareholder’s interest” in mind. Always, research the track record.

Who Is Parker “Pete” Petit?

Parker H. “Pete” Petit joined MiMedx Group, Inc. (“MiMedx” or the “Company”) as Chairman of the Board, Chief Executive Officer and President in February 2009. He resigned as CEO and Chairman effective June 30, 2018 and as a director of MiMedx effective September 20, 2018, amid questions arising among the Company’s Board of Directors (the “Board”) regarding the Company’s leadership and direction. On September 20, 2018, the Company announced that Mr. Petit’s separation from the Company would be treated as “for cause.”

In the Company’s View, Mr. Petit Cannot Be Allowed to Return to MiMedx In Any Capacity

In its independent investigation conducted with the assistance of King & Spalding LLP, a nationally recognized law firm, and KPMG LLP, which performed forensic accounting work, the Audit Committee of the Board found that the evidence demonstrated that Mr. Petit and certain members of his management team engaged in longstanding material misconduct, which harmed MiMedx and its shareholders. More specifically, the evidence demonstrated that Mr. Petit and certain members of his management team disregarded accounting rules; undertook improper actions to manage and manipulate the timing and recognition of revenue; made misleading and false statements to the Company’s outside auditors, the Board and the U.S. Securities and Exchange Commission after questions were raised about the Company’s accounting practices; took actions against whistleblowers; and emphasized short-term business goals over compliance and ethics.

Findings from the investigation include evidence demonstrating that Mr. Petit and certain members of his management team took the following actions, among others:

  • Giving a distributor a lucrative consulting contract simultaneously with a large purchase by the distributor near the end of an accounting reporting period;
  • Intentionally shipping products that were not needed by a customer and recording the revenue, while agreeing at the time of shipment to allow the customer to return or exchange the products in a later accounting reporting period, without recording specific provisions for such returns or exchanges;
  • Booking a large sale at the end of a quarter to a distributor that the Company was in the process of buying, for which the Company recognized the revenue but never received payment;
  • Agreeing to “side deals” that allowed the Company’s distributors to return products or pay for product only when they subsequently resold them;
  • Intentionally hiding a “side” arrangement from the Company’s own accountants and outside auditors, which caused the Company to recognize revenue incorrectly and at the time of the original shipment;
  • Deceiving the Company’s auditors and the Board on multiple occasions about the business dealings with these distributors;
  • Falsely testifying under oath about the arrangements with the Company’s largest distributor;
  • Installing a secret video surveillance system to record interviews that he and other former members of management conducted of certain employees and those employees’ discussions amongst themselves without those employees’ knowledge or consent; and
  • Engaging in a pattern of taking action against employees who raised concerns about the Company’s practices, including reassignment, discipline or termination, without conducting a thorough investigation of those concerns.

As a result of these and related activities, the Company under Mr. Petit’s leadership recognized revenues in the wrong accounting reporting period, and in certain instances, improperly recognized revenue altogether. In certain situations, the timing and improper recognition of revenue allowed the Company to meet its published earnings guidance. Absent these apparent revenue management activities, the Company’s results would have fallen short of earnings guidance in these periods.

The U.S. Department of Justice and the U.S. Securities and Exchange Commission are currently investigating Mr. Petit’s conduct.

Mr. Petit is seeking to return to the Company as a director on the Board and to have two of his business associates elected to the Board. The Board unanimously opposes Mr. Petit’s return, and the Board struggles to understand what his nominees would bring to the boardroom. Neither of his fellow nominees appears to have any knowledge of our products or markets, healthcare experience, executive operating experience or public company board experience.

We believe Mr. Petit’s return in any capacity to MiMedx would be extremely damaging to the Company and its relationships with employees, customers, business partners, potential capital sources, law enforcement and regulators.



Snowball Research,

65, Sakhi Garden, 2nd Cross Street,

Okkiam Thoraipakkam, OMR, Chennai, India

Mobile: 979-0937-345



Snowball Research is an independent research firm. We do not provide personal investment advice. Kindly read our Terms of Use

Copyright by Snowball Research / March Intelligence Research LLP.  All rights reserved.